Avance Clinical, a leading Australian and North American CRO, has joined the Global Health Summit campaign. The summit highlights the importance of quality clinical trials as part of the drug development process. The Global Health program brings together business leaders and healthcare specialists from various industries to showcase organisations spearheading health initiatives. The global event takes place on 25-27 May 2023 in Geneva. Avance Clinical CEO Yvonne Lungershausen and Executive VP North American Operations John Mann will be attending the summit to discuss strategies, share knowledge and expertise, and identify opportunities for collaboration.
Avance Clinical has recently been ranked as the world leader in DCT technology adoption by GlobalData and Clinical Trial Arena in the CRO sector. The report found that 46% of Avance Clinical’s trials incorporated some elements of DCT technologies in 2022. Avance Clinical’s unique clinical offering, GlobalReady, enables biotechs to transition to the US seamlessly for later phases and harness significant speed and cost advantages. More than 40 biotech clients are now taking advantage of Avance Clinical’s GlobalReady program.
The company offers quality clinical trials with globally accepted data in Australia, New Zealand, and the US for international biotechs. Avance Clinical is capable of delivering world-class results and high-quality internationally accepted data for FDA and EMA review. The CRO uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes.
For more information about Avance Clinical’s programs, please visit:
– Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/
– Learn about the ClinicReady model here https://www.avancecro.com/about-clinicready/
– Learn about the GlobalReady model here https://www.avancecro.com/avance-clinical-north-america-operations/
For more information about running your study with Avance Clinical, please contact: enquiries@avancecro.com
